{
    "nct_id": "NCT03414983",
    "official_title": "An Open-Label Exploratory Phase 2/3 Study of Nivolumab With Standard of Care Therapy vs Standard of Care Therapy for First-Line Treatment of Metastatic Colorectal Cancer",
    "inclusion_criteria": "* Histologically confirmed metastatic colorectal cancer, not amenable to curative resection\n* No prior chemotherapy for metastatic colorectal cancer\n* ECOG Performance Status of 0-1\n* Ability to provide adequate tissue sample\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* Patients with clinically relevant medical history, including autoimmune disease, cardiovascular disease, hepatic disease or bleeding disorders\n* Prior treatment with an anti-PD-1, anti-PD-L1, anti-PD-L2, or anti-CTLA-4 antibody, or any other antibody or drug specifically targeting T-cell co-stimulation or checkpoint pathways\n* Any positive test result for hepatitis B virus or hepatitis C virus indicating presence of virus\n\nOther protocol-defined inclusion/exclusion criteria apply",
    "miscellaneous_criteria": ""
}